GLP-certified viral testing and clearance services
Syngene offers GLP-certified viral testing and clearance services with flexible scheduling and rapid turnaround, supporting over 100 global clinical programs. Their facility is India’s only GLP-certified site for viral safety studies, ensuring compliance with FDA, EMA, and WHO regulations. Services include viral clearance studies, cell bank testing, and in-process/batch testing for biologics.
Your one-stop-shop for mAb clinical and commercial manufacturing
Every biologics journey begins with uncertainty. That’s why, at Syngene, we take the first step for you. We initiate Cell Line Development immediately, saving you up to four months while you secure approvals and funding. This early action places your program on a solid footing, reducing both technical and timeline risks. This isn’t just a […]
Transforming Cell Line Development with Syngene’s SynWeave™ Platform
Built on a proprietary CHO cell line and transposon-based technology, SynWeave™ enables the rapid generation of high-yield, stable, and homogeneous clones. The platform integrates advanced clone screening using the Ambr-250 bioreactor, allowing for comprehensive evaluation of titer, key product quality attributes, and process parameters, accelerating your path to robust cell line development.
Syngene’s new biologics facility in the U.S.
Our expanded biologics manufacturing facility in Bayview, Maryland marks a strategic step forward in meeting the growing needs of our global customers. The addition of this facility increases Syngene’s total single-use bioreactor capacity to 50,000 liters, featuring 2,000 and 4,000 liters bioreactors designed to deliver economies of scale.
Your one-stop-shop for XDCs
Syngene offers an integrated bioconjugation platform for XDCs, providing end-to-end support from antibody discovery to GMP manufacturing at up to 1 kg scale. Their expertise covers diverse conjugation technologies, payload and linker chemistry, and advanced analytical and bioassay support. Syngene ensures single-source manufacturing of antibodies, peptides, oligonucleotides, payloads, and linkers, minimizing risk and delays.
Plasmid, mRNA, & Viral Vector Manufacturing: Scaling for the Gene Therapy Boom
Explore how plasmid DNA, mRNA CDMO, and viral vector manufacturing are scaling to meet the rising demand of AAV gene therapy and genetic medicines. Read on to know more.
Integrated Innovation Partners: The Strategic Edge in Modern Drug Development
Publication: Pharmaceutical Technology Focus
Beyond timelines: How Syngene redefines customer-centric project management
Customer-centric pharma project management software for CRDMO programs—integrating metrics, feedback, and risk on one platform to deliver with speed and quality.
Translational Research at Syngene: From Discovery to Personalized Medicine
Syngene’s translational research speeds drug discovery and development and enables personalized medicine with robust models and biomarkers. Explore the approach.
Batch Manufacturing vs Continuous Manufacturing with Process Analytical Technology
Batch vs continuous manufacturing explained, how process analytical technology enables control and real-time release testing, and when each mode fits best.